The role of the brainstem in migraine:Potential brainstem effects of CGRP and CGRP receptor activation in animal models by Holland, Philip Robert et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1177/0333102418756863
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Holland, P. R., Saengjaroentham, C., & Vila-Pueyo, M. (2018). The role of the brainstem in migraine: Potential
brainstem effects of CGRP and CGRP receptor activation in animal models. Cephalalgia.
https://doi.org/10.1177/0333102418756863
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
1 
 
The role of the brainstem in migraine: Potential 
brainstem effects of CGRP and CGRP receptor 
activation in animal models 
 
 
Philip Robert Holland*, Chonlawan Saengjaroentham and Marta Vila-Pueyo  
 
 
 
Headache Group, Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and 
Neuroscience, King’s College London. UK. 
 
 
 
 
 
*Corresponding author:  
Dr Philip R Holland 
Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & 
Neuroscience, King’s College London, 125 Coldharbour Lane, London, UK 
Telephone: +44 02078484222 
Email: Philip.holland@kcl.ac.uk 
 
 
2 
 
Abstract 
Background: Migraine is a severe debilitating disorder of the brain that is ranked as the 6th most 
disabling disorder globally, with respect to disability adjusted life years and there remains a 
significant unmet demand for an improved understanding of its underlying mechanisms. In 
conjunction with perturbed sensory processing, migraine sufferers often present with diverse 
neurological manifestations (premonitory symptoms) that highlight potential brainstem 
involvement. Thus, as the field moves away from the view of migraine as a consequence of purely 
vasodilation to a greater understanding of migraine as a complex brain disorder, it is critical to 
consider the underlying physiology and pharmacology of key neural networks likely involved.  
Discussion: The current review will therefore focus on the available evidence for the brainstem as 
a key regulator of migraine biology and associated symptoms. We will further discuss the potential 
role of CGRP in the brainstem and its modulation for migraine therapy, given the emergence of 
targeted CGRP small molecule and monoclonal antibody therapies. 
Conclusion: The brainstem forms a functional unit with several hypothalamic nuclei that are 
capable of modulating diverse functions including migraine-relevant trigeminal pain processing, 
appetite and arousal regulatory networks. As such, the brainstem has emerged as a key regulator 
of migraine and is appropriately considered as a potential therapeutic target. While currently 
available CGRP targeted therapies have limited blood brain barrier penetrability, the expression 
of CGRP and its receptors in several key brainstem nuclei and the demonstration of brainstem 
effects of CGRP modulation highlight the significant potential for the development of CNS 
penetrant molecules. 
 
Keywords: Migraine, Brainstem, CGRP. 
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Introduction 
Migraine is a severe debilitating disorder of the brain that has troubled humans for centuries (1). 
Despite representing the 6th most disabling disorder globally (2), and the most disabling 
neurological condition with respect to disability adjusted life years, there remains a significant 
unmet demand for an improved understanding of the underlying disease mechanisms. Several 
theories have been proposed for migraine-related pain, including vasodilation (3, 4), neurogenic 
inflammation (5) and activation of the trigeminal pain processing primary afferent nociceptors that 
innervate the intra- and extra-cranial structures of the head (3, 6). In conjunction with the 
developing clinical picture, whereby migraine is considered a multiphasic disorder, current 
theories of migraine propose a complex neural origin with subsequent vascular involvement (6, 7). 
While head pain is a seminal characteristic of migraine (8) patients often present with several 
associated neurological symptoms. These include perturbed sensory responses to light 
(photophobia), sound (phonophobia), smell (osmophobia) and touch (allodynia) (9). In addition to 
this abnormal sensory processing, cognitive, emotional and motor abnormalities are commonly 
reported by migraine patients that may be confounded by several comorbid conditions including 
insomnia (10) and depression (11). Given the diversity of symptoms, migraine likely involves the 
interaction of several neural networks that regulate these diverse functions (e.g. nociception, 
arousal and appetite) (7). As evidenced by the presence of several common premonitory 
(prodromal) symptoms (12) that include disrupted homeostatic mechanisms regulating sleep/wake 
and appetite regulation (e.g. fatigue, yawning, loss of appetite). Thus, as the migraine field moves 
away from the view of migraine as a consequence purely of vasodilation (13-15) to a greater 
understanding of migraine as a brain disorder (1, 6, 7), it is critical to consider the underlying 
pathways known to be involved in the diverse symptoms of migraine. In doing so, it is further 
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important to consider if anti-migraine therapeutic agents, such as targeted calcitonin gene-related 
peptide (CGRP) modulation, may in part act via these networks? As such, the current review will 
focus on the available evidence for the brainstem as a key regulator of migraine biology. We will 
further discuss the potential role of CGRP in the brainstem and its modulation for migraine therapy, 
given the emergence of targeted CGRP small molecule and monoclonal antibody therapies. 
 
Migraine-related pain processing and the brainstem 
Undoubtedly, one of the most salient features of migraine is the severe debilitating often unilateral 
pulsating head pain that is characteristic of the condition. This is borne from the activation, or 
perceived activation, of the pain processing trigeminovascular system that processes sensory 
information from the intra- and extra-cranial structures of the head and face (Figure 1). The exact 
role of trigeminovascular activation is still debated. Does an underlying CNS disruption result in 
the diverse symptoms associated with migraine, whilst driving aberrant trigeminovascular 
activation, or is trigeminovascular activation sufficient to trigger an attack and drive the diverse 
symptoms? Irrespective of the sequence of events, it is clear that the pain processing 
trigeminovascular system and its central projections represent a key interface between migraine-
related pain and its associated non-pain features (Figure 2). As such, activation of the 
trigeminovascular system has been consistently used as a preclinical model of migraine-related 
pain processing (nociception). Primary sensory afferents arising in the trigeminal ganglion (TG) 
project peripherally to the intra- and extracranial structures, including the pial and dural blood 
vessels (3, 16, 17), as well as projecting centrally to the trigeminal nucleus caudalis and its cervical 
boundaries (18-23), giving rise to the trigeminocervical complex (TCC) (Figure 1). From the TCC, 
second order neurons ascend in the trigemino- and quintothalamic tracts where they primarily 
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synapse on ventral posteromedial nucleus of the thalamus (24-28), before being widely distributed 
throughout the cortex for the integration of sensory, affective and cognitive aspects of pain. 
Critically, these ascending trigeminothalamic projections form additional connections with areas 
of the brainstem including the periaqueductal grey (PAG), rostral ventromedial medulla (RVM), 
nucleus raphe magnus (MRN) and the locus coeruleus (LC) (24, 29), as well as to various 
hypothalamic nuclei (30-34). 
The importance of the trigeminal-brainstem interactions is highlighted in several neuroimaging 
studies that demonstrate brainstem activation during spontaneous (35) and triggered attacks (36). 
Whilst this activation was originally suggested to be in response to the developing headache, recent 
observations have highlighted that brainstem activation occurs during the earliest premonitory 
phases (37) prior to the headache. This is further supported by the demonstration of altered 
brainstem functional connectivity (hypothalamus-PAG) in a temporally defined phase prior to the 
onset of spontaneous migraine attacks (38). Despite the clear evidence for brainstem involvement, 
the specific brainstem structures involved are still debated due to the limited resolution of 
neuroimaging approaches. Further, it is not clear if this altered brainstem activation is occurring 
independent of an increasing activation of the trigeminovascular system, as it has been shown that 
the TCC increases its responsiveness to noxious intranasal stimuli as the next migraine attack 
approaches (39). The brainstem may act as a component of a homeostatic regulatory network that 
monitors and reacts to increasing trigeminovascular activity in response to endogenous and 
exogenous signals that can predispose an individual to attacks. 
In addition to receiving direct ascending TCC projections and being activated in response to 
nociceptive durovascular stimulation in animal models (19, 40-44), these brainstem structures, that 
likely include the PAG, LC, RVM and MRN are intrinsically linked throughout the 
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trigeminovascular system, including to higher order structures such as the hypothalamus and 
thalamus (Figure 1) (1). This diverse network of brainstem nuclei is ideally positioned to integrate 
trigeminal mediated signals with neural networks regulating migraine-associated symptoms 
(Figure 2) and represents a potential target for neuromodulatory and pharmacological approaches 
for migraine. 
 
The Brainstem and homeostatic regulation 
The hypothalamus has emerged as a key regulator of homeostatic mechanisms (45), sensing 
intrinsic and extrinsic signals while orchestrating appropriate behavioural responses. While the 
hypothalamus resides within the diencephalon, it is intrinsically linked with several brainstem 
nuclei forming a functional homeostatic regulatory network. As such, the brainstem plays a 
significant role in multiple migraine-relevant biological functions (as detailed in Figure 2). For 
example, they play a key role in the integration of local and circulating factors that convey 
information regarding energy balance acting to regulate appetite and energy expenditure (46). 
Vagal afferents from the gastrointestinal tract signal via the nucleus of the solitary tract (NTS) and 
the area postrema (AP; also plays a role in nausea (47)) to the hypothalamic nuclei regulating 
appetite. Critically, this appetite-regulating pathway, including the AP and NTS has been shown 
to express functional CGRP receptor components (Figure 3 and Table 1), while lesions in the area 
of the AP/NTS abolishes CGRP induced anorectic effects (48). It is noteworthy that the AP is 
devoid of the BBB (49), suggesting it is amenable to peripherally administered CGRP therapies; 
however, the functional relevance of this localized BBB permeability remains to be determined 
(see section on CGRP and the BBB). 
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Further, several brainstem nuclei regulate arousal levels (Figure 2) and therefore have been linked 
to the presence of abnormal fatigue-like symptoms during migraine (12, 50). The majority of these 
structures, including the PAG and LC, receive wake-promoting projections from the hypothalamus 
(for review see (51)), contain CGRP fibers/cell bodies and express CGRP receptor components 
(52-55) (see Figure 3 and Table 1 for detailed distribution). Given their established roles in the 
modulation of trigeminovascular activity and cerebral blood flow (56-59) they likely form a key 
interface between migraine and its association with sleep/wake disturbances (60). As such, the 
brainstem is ideally positioned to regulate several biological functions related to migraine, 
including appetite and fatigue (arousal dysregulation), is abnormally active during the earliest 
attack phases and has been proposed to play a role in attack initiation. 
 
Table 1. CGRP receptor expression, CGRP binding patterns and CGRP expression in 
selected brainstem nuclei.  
The data is further presented in figure form in figure 3. AP; area postrema, CB; cell bodies, CLR; 
calcitonin receptor-like receptor, DMV; dorsal motor nucleus of the vagal, DR; dorsal raphe, F; 
Fibers, LC; locus coeruleus, MK-3207; CGRP receptor antagonist, Mod; moderate, MRN, nucleus 
raphe magnus, NTS; nucleus of the solitary tract, PAG; periaqueductal gray, RAMP1: receptor 
activity modifying protein 1, RCP, receptor component protein, SuS; superior salivatory nucleus, 
TCC; trigeminocervical complex, VN; vestibular nuclei
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 CGRP receptors components/CGRP Binding CGRP Expression Species Ref 
AP CLR & RAMP1 (Protein & mRNA); MK-3207 Binding N/A Primate (53) 
 N/A F (High) Alpaca (61) 
DMV RAMP1 (F) CB Rat (62) 
 RCP (Mod CB) CB (Mod) Rat (54) 
 N/A F (Low); CB (High) Alpaca (61) 
 CLR & RAMP1 (Protein & mRNA); MK-3207 Binding N/A Primate (53) 
 GRP Binding (High) N/A Human/Rat (63) 
DR RAMP1 (mRNA); CLR & RAMP1 (Protein); MK-
3207 Binding 
CGRP Binding (Mod) 
N/A 
 
N/A 
Primate 
 
Human 
(53) 
 
(63) 
 N/A F (Low); CB (High) Alpaca (61) 
 RCP (Mod Cell Bodies) Axons & CB (Low) Rat (54) 
 LC N/A CB (80%); F (Low) Human (55) 
 RAMP1 & CLR (F & CB) CB Rat (62) 
 N/A F (Mod) Alpaca (61) 
 RCP (Mod CB) CB (Mod) Rat (54) 
 CGRP Binding (High) N/A Human/Rat (63) 
MRN RAMP1 & CLR (F & CB) CB Rat (62) 
NTS Absent F & CB Rat (62) 
 N/A F (High) Alpaca (61) 
 RCP (Mod CB) Axons (Mod) Rat (54) 
 CGRP Binding (High) N/A Human/Rat (63) 
PAG CLR & RAMP1 (Protein & mRNA); MK-3207 Binding N/A Primate (53) 
 RCP (Mod CB) Axons (Low) Rat (54) 
 CLR & RAMP1 (Cell Bodies) N/A Rat (64) 
 CLR & RAMP1 mRNA (High); RCP mRNA (Mod) CALCA mRNA (Low) Rat (65) 
 N/A F & CB (Low) Alpaca (61) 
 CGRP Binding (Moderate) N/A Rat (66) 
 CGRP Binding (High) N/A Human/Rat (63) 
SuS N/A Fibers Rat (67) 
TCC CLR & RAMP1 (Protein & mRNA); MK-3207 Binding N/A Primate (53) 
 RCP (Mod CB) Axons (Mod) Rat (54) 
 CLR/RAMP1 Present (not defined) Rat (62) 
 CLR mRNA (High); RAMP1 & RCP mRNA (Mod) CALCA mRNA (Mod) Rat (65) 
 CGRP Binding (High) N/A Human (63) 
 CLR & RAMP1 (CB) N/A Rat (64) 
 CGRP Binding (Mod) N/A Rat (66) 
VN N/A F & CB Rat (68) 
 N/A CB Rat (69) 
 CGRP Binding (Mod) N/A Rat (66) 
 CGRP Binding (High/Mod) N/A Human/Rat (63) 
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Calcitonin Gene-Related Peptide 
CGRP belongs to the calcitonin family and is synthesized from two genes; the CALCA gene gives 
rise to calcitonin or αCGRP and the distinct CALCB gene gives rise to βCGRP (57). The two 
isoforms are similar in homology and biological function, however αCGRP is classically 
considered to predominate in the peripheral and central nervous system, whereas βCGRP 
predominates in the enteric nervous system (70), as such we will focus on αCGRP (described as 
CGRP from this point onward). Following the synthesis of CGRP, a process that remains poorly 
understood, the neuropeptide is stored in large, dense-core vesicles within nerve terminals (71). 
As discussed previously, CGRP is expressed in sensory afferents innervating the cranial 
vasculature (72) where it can act as a potent vasodilator. However, its widespread distribution 
throughout the trigeminal ganglion and afferents, brainstem, diencephalic and particularly the 
cerebellum, highlights its diverse role in neurotransmission (73). The CGRP receptor consists of 
three key components: (i) the calcitonin receptor-like receptor (CLR), (ii) a receptor activity 
modifying protein (RAMP) and (iii) an additional receptor component protein (RCP). The CLR 
belongs to the same “secretin-like” family of G protein-coupled receptors as those for calcitonin, 
vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide and when 
expressed independently it is unresponsive to CGRP. CLR requires a RAMP to regulate its 
functional specificity and membrane translocation (73). The association of CLR with RAMP1 
denotes the established CGRP receptor, CLR and RAMP2 results in the adrenomedullin receptor 
(AM1 receptor) and CLR and RAMP3 results in an additional adrenomedullin receptor (AM2 
receptor). While the primary receptor for CGRP is considered to be the CLR/RAMP1 complex, it 
is known that in vitro CGRP shows partial affinity for the CLR/RAMP3 AM2 receptor (74) and 
for a recently described third potential CGRP receptor resulting from the combination of the 
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calcitonin receptor and RAMP1 (75). Given the widespread distribution of CLR, it is perceived 
that individual RAMPs are responsible for receptor tissue (76) and species specificity (77).  
The above combination of receptor proteins and RAMPs constitutes a functional receptor; 
however, the presence of a third RCP is essential for optimal function (78). The RCP is a small 
hydrophilic membrane-associated protein that enhances the signal transduction of both CGRP and 
adrenomedullin receptors, suggesting that it may represent a novel therapeutic target for the 
inhibition of all identified potential CGRP receptors. 
 
Targeted CGRP Therapies and the Blood-Brain Barrier (BBB) 
Currently targeted CGRP therapies are focused on either acute CGRP receptor antagonism 
(gepants) or prophylaxis with monoclonal antibodies that bind to the CGRP peptide or its receptor 
(umabs). Targeted antagonism of the CGRP receptor has demonstrated significant clinical promise 
(79). The initial doses required for clinical efficacy raised the possibility that the small molecules 
may have to penetrate the BBB to exert their effects (80). This was supported by previous animal 
research demonstrating that olcegepant inhibited capsaicin-induced sensitization in the TCC with 
little impact on the TG (81). Despite this initial focus on potential central effects, telcagepant has 
subsequently been shown to bind to the TG of rhesus monkeys, while failing to displace central 
binding of the radiolabeled CGRP PET ligand MK-4232 (82), suggesting limited CNS 
bioavailability in humans. This proposed peripheral site of action is further supported by the 
demonstration of a clear clinical efficacy for umabs (83), whose large molecular weight largely 
preclude BBB penetration, with only 0.1% of systemic values estimated to gain access to the CNS. 
In view of this relative lack of BBB permeability, it has alternatively been proposed that the BBB 
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is compromised during migraine attacks and, as such, the precise location of action of targeted 
CGRP therapies and existing migraine therapies remains a consistently debated topic. It should, 
however, be noted that studies utilizing radiolabeled dihydroergotamine found no evidence for 
BBB disruption during migraine attacks (84).  
Independent of the potential disruption of the BBB during migraine, it is clear that specific brain 
areas lack a functional BBB and, as such, these sites offer a potential conduit for larger molecules 
to enter the CNS and/or facilitate signaling via widespread CNS projections. Specific areas include 
the circumventricular organs, meningeal arteries, pineal gland, preoptic recess and endothelium of 
the choroid plexus. The circumventricular organs are particularly interesting (85), these include 
both sensory (subfornical organ (SFO), vascular organ of the lamina terminalis (OVLT) and the 
AP) and secretory organs (neurohypophysis, median eminence and the pineal gland). The SFO, 
OVLT and AP are reciprocally interconnected with each other and with several hypothalamic and 
brainstem nuclei that play important roles in migraine pathophysiology. The SFO receives 
significant afferent input from the lateral and anterior hypothalamus, as well as the paraventricular 
nucleus, while its efferent projections signal to the suprachiasmatic nucleus and paraventricular 
nucleus. The OVLT is additionally innervated by direct projections from the dorsomedial, 
ventromedial and preoptic hypothalamic nuclei, as well as from the PAG and LC. It sends efferent 
fibers to the paraventricular, supraoptic, preoptic and lateral hypothalamic nuclei, as well as to the 
PAG and LC. In terms of direct brainstem access, the AP forms part of the vagal complex in 
conjunction with the NTS and the DMV. It is reciprocally interconnected with the other 
circumventricular organs in addition to the NTS and RVM, and receives direct afferent projections 
from the paraventricular nucleus. The AP has been shown to express CGRP receptors (Figure 3 
and Table 1)(52, 53) and together with other circumventricular organs is involved in the regulation 
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of feeding/energy homeostasis and nausea. The functional importance for these BBB openings in 
relation to migraine therapy remain to be explored. 
In light of this limited CNS penetrability, the concept of exploring brainstem effects of current 
CGRP therapies appears on the surface a fruitless endeavor.  Yet, as will be discussed below, there 
is clear evidence for potential CNS mechanisms of CGRP modulation. This is in agreement with 
the demonstration of brainstem effects of triptans (58), despite variable BBB penetrability that has 
ultimately led to the development of a novel class of CNS penetrant, centrally acting 5-HT1F 
receptor agonists (ditans) (86). Taking this into consideration, it is reasonable to conclude that the 
development of CNS penetrant CGRP targeted therapies or novel BBB transporters remains a valid 
target for migraine therapy. 
 
CGRP expression in the brainstem 
As detailed above, αCGRP (herein denoted as CGRP) predominates in the CNS (70) and its 
expression has been widely mapped throughout the brainstem ((52-55), which the following 
section is based upon, see Figure 3 and Table 1 for a detailed breakdown of expression). Given the 
widespread expression of CGRP and its receptors, it has been linked to a number of functions 
ranging from nociception (87) to vestibular regulation and motion sickness (68), all of which have 
been linked to migraine. CGRP expression is largely conserved across species, including human, 
monkeys, cats and rodent tissue, and, as such, expression data is discussed independent of species 
except where notable differences have been identified. Small and medium size CGRP-expressing 
trigeminal primary afferents arising from the TG synapse within the superficial laminae of the 
TCC, where they synapse on ascending trigeminothalamic projection neurons (88). Clinical and 
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preclinical data consistently highlight the importance of the TCC as a key transitional interface in 
the processing of trigeminovascular nociception, that additionally receives descending modulatory 
inputs from several brainstem and higher order structures (Figure 1). The highest density of CGRP 
immunoreactivity in the brainstem has been reported in the LC (55, 89), with moderate expression 
observed in the PAG. Additional expression has been observed throughout several brainstem 
structures, including the dorsal raphe nuclei (DR), spinal trigeminal nuclei and vestibular nuclei 
(VN). Given the complexity of the CGRP receptor structure, a variety of approaches have 
attempted to visualize CGRP receptor distribution in the brainstem. The RCP component 
demonstrates high expression levels in the PAG and DR nuclei of rats, with moderate expression 
in the ventral tegmental area and LC; while CLR is observed in the human brainstem nuclei 
including the NTS and AP. In support of the widespread distribution of CGRP receptors, a recent 
study utilizing [11C]MK-4232 as a selective marker for the CLR/RAMP1 complex demonstrated 
widespread moderate distribution in the human and primate brainstems, although specific 
brainstem nuclei were not defined. (82). 
 
Brainstem effects of CGRP and CGRP receptor modulation 
CGRP is widely distributed in the brainstem, yet relatively little is known regarding its specific 
function. Of particular importance to migraine is the predominance of CGRP in small to medium 
trigeminal primary afferents that synapse in the dorsal horn of the TCC. CGRP release at these 
central synapses is suggested to increase nociceptive transmission. Local delivery of CGRP onto 
dural nociceptive-responsive TCC neurons in the cat resulted in excitation of over 40% of neurons 
tested. Further, CGRP antagonism with the truncated form of CGRP (CGRP8-37) or the small 
molecule antagonist olcegepant (BIBN4096BS) inhibited the response of the majority of neurons 
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to local glutamate, suggesting a post-synaptic mechanism of action (90). In agreement, ex vivo 
studies on medullary brain slices demonstrated increased CGRP release in response to potassium 
chloride and capsaicin that was inhibited by naratriptan. These results highlight the importance of 
CGRP release from central terminals in the TCC for trigeminal nociception and suggest that TCC 
CGRP modulation may be a potential mechanism of action for the triptans (91). 
As noted, the highest expression levels of CGRP in the brainstem are found in the noradrenergic 
LC (55), an area involved in the regulation of arousal (92), autonomic (93), stress (94), nociceptive 
functions (95) and cerebral blood flow (59, 96, 97) (Figure 2). Preclinically, the LC is responsive 
to activation of the trigeminovascular system (98) and known clinical migraine triggers, including 
nitroglycerin, induce LC activation (99); while its stimulation in the cat impacts cerebral blood 
flow inducing hypoperfusion (59, 96, 97) reminiscent of the functional hyperemia observed during 
cortical spreading depression. The LC is further activated by CTR-stimulating peptide 1, 
suggesting that it is sensitive to circulating CGRP levels that may act to regulate energy 
homeostasis (100). Inhibition of CGRP receptors with olcegepant in vitro in organotypic brain 
slice cultures containing the LC increases noradrenaline release, suggesting a possible action of 
CGRP targeted therapies on intrinsic CGRP signaling in the LC, which could impact on migraine 
pathophysiology (101). While the exact functions of the LC remain to be fully elucidated, its role 
as a major arousal promoting network that demonstrates clear diurnal activation patterns (102), 
has highlighted its potential as a regulator of migraine biology. This link has been recently 
strengthened by the demonstration of altered trigeminovascular dural nociceptive evoked 
responses following lesioning of the LC (103), whereby acute lesioning or chronic ablation of the 
LC reduced dural-nociceptive evoked TCC responses. 
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The PAG is perhaps the most prominent brainstem nuclei in migraine research since Weiller et al. 
(35) demonstrated its activation during a spontaneous migraine attack, with subsequent imaging 
studies highlighting abnormal functional activation and network connectivity during the 
premonitory phase (37, 38). Preclinically, this is in agreement with abnormal functional 
connectivity states following repetitive dural inflammatory soup application (104), suggesting that 
abnormal PAG signaling may be an important regulator of/response to recurrent attacks. Electrical 
or chemical activation of the ventrolateral subunit of the PAG (vlPAG) inhibits durovascular 
evoked trigeminal nociceptive processing in the TCC (105-107), including local application of a 
triptan (58). It has further been demonstrated that orally administered rizatriptan, that is thought to 
have a degree of central anti-nociceptive effects (108), reduces nitroglycerin-induced elevation of 
CGRP in the PAG (109), thus highlighting the potential of targeting such brainstem nuclei in 
migraine therapy. While the PAG is protected by the BBB, direct administration of CGRP into the 
PAG has been shown to potentiate trigeminovascular nociception at the level of the TCC, and both 
CGRP8-37 and olcegepant inhibit TCC dural-nociceptive evoked responses in the rat (64). It must 
be noted, however, that direct administration of CGRP into the MRN of rats demonstrated an anti-
nociceptive effect on hind-paw thermal and mechanical stimuli (110). As such, there is evidence 
for complex pro- and anti-nociceptive effects of CGRP signaling in brainstem nuclei that may be 
dependent on the specific nuclei or the pain modality being tested. 
The RVM is a key output relay of the PAG involved in the indirect modulation of pain signaling. 
It has reciprocal connections with the PAG and TCC (111-113) and is known to contain both anti-
nociceptive off and pro-nociceptive on cells (113) that can regulate trigeminovascular nociception. 
For example, repetitive application of an inflammatory soup to the dura mater of rats results in 
heightened mechanosensation via an action on RVM mediated descending facilitation (41). This 
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pathway has further been implicated in the regulation of homeostatic mechanisms as on-cells are 
state dependently active during wakefulness; however, they fall silent during feeding. Off-cells 
show an opposite response to feeding in that they are constituently activated during feeding, 
suggesting a role in the integration of energy homeostasis (114, 115). In the context of CGRP, 
there is little evidence for CGRP/CGRP receptor expression within the RVM (116); however, it is 
likely that the RVM acts downstream of other brainstem and hypothalamic nuclei including the 
PAG that do show responsiveness to CGRP signaling (64). 
Patients with migraine often report vertigo (117), which is regulated by the vestibular nuclei in the 
brainstem. CGRP is expressed throughout the various vestibular nuclei (118-120) (Figure 3 and 
Table 1), with preclinical studies identifying increased CGRP expression in a rotational model of 
motion sickness (121). Rats exposed to repeated bouts of rotary stimulation had an increased 
number of CGRP expressing neurons throughout the vestibular nuclei, including the vestibular 
efferent nucleus at the level of the facial nerve genu. This is in agreement with a reduced vestibule-
ocular reflex in CGRP null mice (122) highlighting the potential role of elevated CGRP signaling 
as an underlying mechanism for the association between migraine and vertigo (123). 
 
Conclusion 
The brainstem forms a key functional unit with key hypothalamic nuclei that is capable of 
modulating diverse functions including migraine-relevant trigeminal pain processing, appetite and 
arousal regulatory networks. While the resolution of human neuroimaging precludes the 
identification of specific nuclei, it does highlight the abnormal activation of a brainstem nuclear 
complex during the earliest premonitory phase that continues into the headache phase and remains 
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after triptan-induced pain relief (35). As such, the brainstem has emerged as a key regulator of 
migraine biology and is appropriately considered as a potential therapeutic target. CGRP and its 
receptors are expressed throughout the brainstem (detailed in Figure 3 and Table 1) where their 
modulation has been shown to impact on trigeminal mediated pain and associated migraine-related 
functions. Current evidence suggests that the majority of CGRP targeted therapies, including 
monoclonal antibodies targeting CGRP or its receptor, do no cross the BBB in any significant 
quantity. Despite this lack of BBB penetration (notwithstanding localized access at areas such as 
the AP), there is sufficient clinical and experimental data to suggest that targeting central 
mechanisms including via brainstem nuclei may offer additional therapeutic benefits. 
 
Article Highlights 
• The brainstem is a key region involved in the regulation of homeostatic mechanisms that 
play a prominent role in migraine including fatigue (arousal dysfunctions) and appetite. 
• Several brainstem nuclei contain CGRP and its receptor and local application of CGRP 
agonists and antagonists can modulate trigeminovascular nociception. 
• Modulation of brainstem CGRP signaling remains a valid target for the development of 
brain penetrant CGRP targeted therapies. 
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Review Process 
We searched PubMed, Medline and Web of Science with the search terms “migraine”, 
“brainstem”, “CGRP”, “CGRP receptor”, “periaqueductal gray”, “locus coeruleus”, “rostral 
ventromedial medulla”, “trigeminal” and combinations therein. We reviewed bibliographies of 
relevant articles and identified articles through additional author searches to include mostly 
preclinical articles and occasional congress proceedings/abstracts published in English. The final 
reference list was then selected based on the authors perception of the relevance of the article to 
the scope of this review. 
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Figure 1: Ascending and descending projections via the brainstem in migraine.  
The trigeminal ganglion (TG) gives rise to the pseudo-unipolar trigeminal primary afferents which 
synapse on the intra- and extra-cranial structures (blood vessels and dura mater) as well as the 
spinal cord trigeminocervical complex (TCC). Second-order neurons from the TCC ascend in the 
trigeminothalamic tract synapsing on third-order thalamocortical neurons before passing to the 
cortex. Direct and indirect ascending projections additionally exist to key brainstem and 
diencephalic nuclei including the locus coeruleus (LC), periaqueductal grey (PAG) and 
hypothalamus. The TCC is under the regulation of direct and indirect descending modulatory 
pathways. Direct and indirect projections (via the hypothalamus) exist from the cortex, whilst key 
brainstem nuclei including the PAG, LC and rostral ventromedial medulla (RVM) provide 
modulatory pathways that arise within the nuclei or are under top down regulation. This complex 
network of descending modulatory circuits potently regulates the TCC providing pro- and anti- 
nociceptive drive. 
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Figure 2: The functional importance of selected brainstem nuclei with respect to migraine-
associated symptoms. 
AP; area postrema, DMV; dorsal motor nucleus of the vagal, DR; dorsal raphe, LC; locus 
coeruleus, MRN, nucleus raphe magnus, NTS; nucleus of the solitary tract, PAG; periaqueductal 
gray, SPG; sphenopalatine ganglion, SuS; superior salivatory nucleus, TCC; trigeminocervical 
complex, TG; trigeminal ganglion, VN; vestibular nuclei. 
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Figure 3: Overview of CGRP expression in selected brainstem nuclei. 
(A) The expression of CGRP fibers (red), cell bodies (soma, blue) or both (green) in selected 
brainstem nuclei are shown. (B) The expression of calcitonin receptor-like receptor (CLR, red), 
receptor activity modifying protein 1 (RAMP 1, blue) or both (green) in selected brainstem nuclei 
are shown. Where CLR and RAMP 1 expression is unknown, CGRP receptor binding has been 
used to highlight the presence of functional CGRP receptors (light green). The above information 
is taken from the references and data presented in Table 1. AP; area postrema, DMV; dorsal motor 
nucleus of the vagal, DR; dorsal raphe, LC; locus coeruleus, MRN, nucleus raphe magnus, NTS; 
nucleus of the solitary tract, PAG; periaqueductal gray, SPG; sphenopalatine ganglion, SuS; 
superior salivatory nucleus, TCC; trigeminocervical complex, TG; trigeminal ganglion, VN; 
vestibular nuclei. 
 
 
